Stocktoria
Voyager Therapeutics, Inc. VYGR
Voyager Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.4M | $80.0M | $250.0M | $40.9M | $37.4M | $171.1M | $104.4M | $7.6M | $10.1M | $14.2M |
| R&D expense | $134.7M | $127.4M | $92.2M | $60.8M | $73.8M | $108.8M | $119.7M | $64.9M | $62.3M | $42.2M |
| Operating income | -$131.8M | -$83.3M | $122.0M | -$50.8M | -$73.6M | $27.4M | -$51.7M | -$91.1M | -$71.9M | -$41.3M |
| Income tax | $144,000 | $665,000 | $1.4M | $16,000 | — | — | — | -$180,000 | — | $52,000 |
| Net income | -$119.7M | -$65.0M | $132.3M | -$46.4M | -$71.2M | $36.7M | -$43.6M | -$88.3M | -$70.7M | -$40.2M |
| EPS (diluted) | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 | $0.98 | $-1.21 | $-2.75 | — | — |
| Operating cash flow | -$132.5M | -$15.3M | $77.9M | -$12.5M | -$53.5M | -$96.7M | $48.7M | -$15.9M | -$61.4M | -$42.5M |
| Free cash flow | -$135.1M | -$18.8M | $74.7M | -$15.0M | -$55.1M | -$108.8M | $40.9M | -$20.2M | -$65.3M | -$47.5M |
| Cash & equivalents | $65.3M | $71.4M | $68.8M | $99.0M | $117.4M | $104.4M | $86.0M | $46.9M | $31.5M | $36.6M |
| Total assets | $252.3M | $393.1M | $351.3M | $159.4M | $193.9M | $261.6M | $354.8M | $177.0M | $184.5M | $189.6M |
| Total liabilities | $56.2M | $93.3M | $115.0M | $100.3M | $98.8M | $107.3M | $255.2M | $130.6M | $50.4M | $53.6M |
| Shareholders' equity | $196.1M | $299.8M | $236.3M | $59.0M | $95.1M | $154.3M | $99.5M | $46.4M | $134.1M | $135.9M |
Growth · year-over-year · Revenue CAGR 12.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -49.5% | -68.0% | +511.2% | +9.3% | -78.1% | +63.9% | +1270.1% | -24.8% | -28.7% | -18.0% |
| Net income growth | — | -149.1% | — | — | -293.8% | — | — | — | — | — |
| EPS growth | — | -138.0% | — | — | -292.9% | — | — | — | — | — |
| Free cash flow growth | — | -125.2% | — | — | — | -365.7% | — | — | — | -218.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.